Scientists resolve how chromosomal mix-ups lead to tumors

March 29, 2012 in Cancer

(Medical Xpress) -- A new study by scientists from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, resolves longstanding questions about the origin of recurrent chromosomal rearrangements — known as translocations — that drive lymphomas and leukemias in humans. Translocations occur when broken strands of DNA from one chromosome are erroneously joined with those of another chromosome, thus deregulating genetic information and leading to cell transformation. Sometimes chromosomal rearrangements can be beneficial, in that they enable the immune system to respond to a vast number of microorganisms and viruses. However, translocations can result in tumors. The study was reported in the journal Nature.

Specific chromosomal translocations driving human have been known since 1960, when scientists in Philadelphia (Peter Nowell and David Hungerford) first visualized one such lesion in patients suffering from chronic myeloid leukemia, an aggressive form of cancer in the blood. The origin of such malignant rearrangements, however, has been unclear. At least three theories have been put forward to explain their etiology: 

  • Translocations between two  are driven primarily by how frequently the genes interact in the nucleus of tumor precursor cells.
  •  
  • Translocating genes undergo DNA damage more frequently than non-translocating genes.
  •  
  • All genes in the genome have about an equal chance of translocating with one another, but certain translocations are particularly selected because they drive cell transformation.
 In the new study, NIAMS scientists used cutting-edge technologies to explore the three theories.  Using immune cells known as B cells, they found that the frequency of DNA damage was directly proportional to the frequency of translocation. Intriguingly, the researchers found that an enzyme, called AID, damages approximately 150 genes in the B cell genome, thus making them susceptible to translocations. Among the targeted genes, many have been previously shown to be translocated in human cancer. Further study also revealed that, in the absence of AID, gene proximity or interaction frequency was the driving force behind translocations.

The new results not only clarify the origin of tumor-inducing translocations, but they also suggest that finding ways to stop AID could potentially prevent the development of many human cancers.

More information: Ofir Hakim et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature DOI: 10.1038/nature10909 [Epub ahead of print]

Journal reference: Nature search and more info website

Provided by National Institutes of Health

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Research identifies a way to make cancer cells more responsive to chemotherapy

Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...

Cancer created 2 hours ago | popularity 5 / 5 (2) | comments 0

Mayo Clinic genomic analysis lends insight to prostate cancer

Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...

Cancer created 2 hours ago | popularity not rated yet | comments 0

When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs

Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...

Cancer created 3 hours ago | popularity not rated yet | comments 0 | with audio podcast

Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...

Cancer created 7 hours ago | popularity not rated yet | comments 0

Protein preps cells to survive stress of cancer growth and chemotherapy

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

Cancer created 7 hours ago | popularity not rated yet | comments 0 | with audio podcast


Glucosamine supplements tied to risk of eye condition

(HealthDay)—Glucosamine supplements that millions of Americans take to help treat hip and knee osteoarthritis may have an unexpected side effect: They may increase risk for developing glaucoma, a small ...

Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

WHO: Scientific red tape mars efforts vs. virus

International efforts to combat a new pneumonia-like virus that has now killed 22 people are being slowed by unclear rules and competition for the potentially profitable rights to disease samples, the head ...

Future doctors unaware of their obesity bias

Two out of five medical students have an unconscious bias against obese people, according to a new study by researchers at Wake Forest Baptist Medical Center. The study is published online ahead of print in the Journal of ...

Scientists discover molecule triggers sensation of itch

Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.